Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Continuous infusion of PTH in vivo results in active bone resorption. To investigate the molecular basis of the catabolic effect of PTH in vivo, we evaluated the role of OPG and RANKL, which are known to influence osteoclast formation and function. Weanling rats fed a calcium-free diet were parathyroidectomized and infused with PTH via an Alzet pump to examine: 1) the changes of serum-ionized calcium and osteoclast number, 2) the expression of OPG/RANKL mRNA and protein, and 3) the expression of osteoblast phenotype bone formation-associated genes such as osteoblast specific transcription factor, osteocalcin, bone sialoprotein, and type I collagen. PTH (1–38) (0.01–20 μg/100 g) continuous infusion for 1–24 h resulted in a dose-dependent increase in serum-ionized calcium in parathyroidectomized rats and a corresponding dose-dependent increase in osteoclast number, indicating an increased bone resorption. At 20 μg/100 g PTH dose level, serum-ionized calcium was 2.1-fold of the vehicle control and not differ...

[1]  K. Chihara,et al.  Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. , 2000, European journal of endocrinology.

[2]  S. Chandrasekhar,et al.  In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early Gene , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Xiao-peng Yu,et al.  Activation of Osteocalcin Transcription Involves Interaction of Protein Kinase A- and Protein Kinase C-dependent Pathways* , 2000, The Journal of Biological Chemistry.

[4]  G. Sandusky,et al.  Immunohistochemical Localization of Selected Early Response Genes Expressed in Trabecular Bone of Young Rats Given hPTH 1-34 , 1999, Calcified Tissue International.

[5]  L. Mosekilde,et al.  Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). , 1999, Bone.

[6]  J. Lorenzo,et al.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. , 1999 .

[7]  T. Tsuboyama,et al.  Expression of the c-fos gene induced by parathyroid hormone in the bones of SAMP6 mice, a murine model for senile osteoporosis , 1999, Mechanisms of Ageing and Development.

[8]  M. Ueda,et al.  Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. , 1999, Gene.

[9]  N. Udagawa,et al.  A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. , 1999, Biochemical and biophysical research communications.

[10]  D. Lacey,et al.  Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors , 1999, Journal of cellular biochemistry.

[11]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[12]  N. Nagata,et al.  Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .

[13]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[14]  A. Harvey,et al.  Intermittent administration of parathyroid hormone (1‐34) stimulates matrix metalloproteinase‐9 (MMP‐9) expression in rat long bone , 1998, Journal of cellular biochemistry.

[15]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[16]  H. Yasuda,et al.  Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. , 1998, European journal of biochemistry.

[17]  N. Udagawa,et al.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.

[18]  N. Udagawa,et al.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.

[19]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[20]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[21]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[23]  T. Martin,et al.  Hormonal Regulation of Osteoclast Function , 1998, Trends in Endocrinology & Metabolism.

[24]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[25]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[26]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[27]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[28]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[29]  A. Harvey,et al.  Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro. , 1997, Bone.

[30]  S. Stevenson,et al.  In vivo demonstration that parathyroid hormone and parathyroid hormone–related protein stimulate expression by osteoblasts of interleukin‐6 and leukemia inhibitory factor , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  J. Bidwell,et al.  In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. , 1995, Bone.

[32]  R. Turner,et al.  Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. , 1995, Endocrinology.

[33]  N. Udagawa,et al.  Modulation of osteoclast differentiation by local factors. , 1995, Bone.

[34]  P. Delmas,et al.  The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? , 1995, Bone.

[35]  O. Tørring,et al.  Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. , 1993, Calcified tissue international.

[36]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[37]  L. Melton,et al.  The prevention and treatment of osteoporosis. , 1992, The New England journal of medicine.

[38]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[39]  J. Hock,et al.  Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  T. Martin,et al.  Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. , 1989, Endocrinology.

[41]  R. Boyce,et al.  Resorption is not essential for the stimulation of bone growth by hPTH‐(1‐34) in rats in vivo , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  J. Hock,et al.  Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. , 1988, Endocrinology.

[43]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  J. Potts,et al.  Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients. , 1981, The Journal of clinical investigation.

[45]  J Reeve,et al.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.

[46]  C. Dunstan.  Osteoprotegerin and Osteoprotegerin Ligand Mediate the Local Regulation of Bone Resorption , 2000 .

[47]  K. Thirunavukkarasu,et al.  Dynamic regulation of RGS2 in bone: potential new insights into parathyroid hormone signaling mechanisms. , 2000, Endocrinology.

[48]  J. Bidwell,et al.  Rat Osteoblast and Osteosarcoma Nuclear Matrix Proteins Bind with Sequence Specificity to the Rat Type I Collagen Promoter1. , 1997, Endocrinology.

[49]  G. Segre,et al.  Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. , 1994, Endocrinology.